AU2001284057A1 - Combination of lipoic acids and conjugated acids for treating diabetic disorders - Google Patents

Combination of lipoic acids and conjugated acids for treating diabetic disorders

Info

Publication number
AU2001284057A1
AU2001284057A1 AU2001284057A AU8405701A AU2001284057A1 AU 2001284057 A1 AU2001284057 A1 AU 2001284057A1 AU 2001284057 A AU2001284057 A AU 2001284057A AU 8405701 A AU8405701 A AU 8405701A AU 2001284057 A1 AU2001284057 A1 AU 2001284057A1
Authority
AU
Australia
Prior art keywords
acids
combination
diabetic disorders
lipoic
treating diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284057A
Inventor
Kai-Uwe Baldenius
Oliver Hasselwander
Martin Jochen Klatt
Klaus Kramer
Loni Schweikert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001284057A1 publication Critical patent/AU2001284057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.
AU2001284057A 2000-09-12 2001-09-11 Combination of lipoic acids and conjugated acids for treating diabetic disorders Abandoned AU2001284057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045059A DE10045059A1 (en) 2000-09-12 2000-09-12 Therapeutic combination of lipoic acid and conjugate acids for the treatment of diabetic disorders
DE10045059.8 2000-09-12
PCT/EP2001/010501 WO2002022111A2 (en) 2000-09-12 2001-09-11 Combination of lipoic acids and conjugated acids for treating diabetic disorders

Publications (1)

Publication Number Publication Date
AU2001284057A1 true AU2001284057A1 (en) 2002-03-26

Family

ID=7655916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284057A Abandoned AU2001284057A1 (en) 2000-09-12 2001-09-11 Combination of lipoic acids and conjugated acids for treating diabetic disorders

Country Status (10)

Country Link
US (1) US20030187058A1 (en)
EP (1) EP1317264B1 (en)
JP (1) JP2004508399A (en)
CN (1) CN1216602C (en)
AT (1) ATE271866T1 (en)
AU (1) AU2001284057A1 (en)
DE (2) DE10045059A1 (en)
DK (1) DK1317264T3 (en)
ES (1) ES2225593T3 (en)
WO (1) WO2002022111A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
DE602004014716D1 (en) * 2004-03-06 2008-08-14 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
JP4556061B2 (en) * 2006-07-27 2010-10-06 ビーエイチエヌ株式会社 Hyaluronic acid production enhancer
WO2008067403A2 (en) * 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
CN101396357B (en) * 2007-09-29 2010-12-29 中国科学院上海生命科学研究院 Use of lipoamide in preventing and treating insulin resistance
WO2009111635A2 (en) * 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
EP4082542A1 (en) 2009-06-15 2022-11-02 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
PT2821405E (en) 2009-06-15 2016-06-14 Encore Health Llc Choline esters for treating presbyopia and cataract
CN101671331B (en) * 2009-09-29 2011-06-01 寿光富康制药有限公司 Lipoyl vildagliptin as well as preparation method and application thereof
JP5245061B2 (en) * 2010-05-12 2013-07-24 ビーエイチエヌ株式会社 Oral antioxidant and beauty method
AU2014321711B2 (en) 2013-09-19 2019-11-14 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
CA2941518A1 (en) 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343593C2 (en) * 1993-12-21 1998-05-20 Asta Medica Ag Use of R - (+) - alpha-lipoic acid, R - (-) - dihydrolipoic acid or the metabolites as well as their salts, esters, amides for the treatment of compensated and decompensated insulin resistance
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
DE69832520T2 (en) * 1997-12-12 2006-08-10 Purdue Research Foundation, West Lafayette USE OF CONJUGATED LINOLEIC ACID FOR THE TREATMENT OF TYPE II DIABETES
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
WO2001056572A1 (en) * 2000-02-02 2001-08-09 Metagenics, Inc. Compositions and methods for promoting healthy joints

Also Published As

Publication number Publication date
DE10045059A1 (en) 2002-03-21
EP1317264B1 (en) 2004-07-28
ES2225593T3 (en) 2005-03-16
CN1216602C (en) 2005-08-31
EP1317264A2 (en) 2003-06-11
ATE271866T1 (en) 2004-08-15
US20030187058A1 (en) 2003-10-02
WO2002022111A2 (en) 2002-03-21
DE50103029D1 (en) 2004-09-02
CN1455670A (en) 2003-11-12
JP2004508399A (en) 2004-03-18
DK1317264T3 (en) 2004-11-29
WO2002022111A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
AU2001284057A1 (en) Combination of lipoic acids and conjugated acids for treating diabetic disorders
AU2004280090B2 (en) Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
BR9814484A (en) "aspartyl protease inhibitor prodrugs"
WO2001019776A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
WO2002062751A1 (en) Novel cystine derivatives and inhibitors for the activation of inflammatory factors
IL148103A0 (en) Novel dicarboxylic acid derivatives with pharmaceutical properties
GEP20032987B (en) Stabilized Solid Compositions Containing Gamma-Aminobutyric Acid Derivatives for Treatment of Neuropathologic Diseases and Process for Preparing The Same
BR0306846A (en) Blood substitute product, composition useful as a blood substitute, method for making a blood substitute product, and method of using a blood substitute product to deliver oxygen to a tissue.
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
EA200500377A1 (en) PYRAZOL DERIVATIVES AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
BG106155A (en) Novel derivatives and analogues of galanthamin
RU94038256A (en) Derivatives of pyrazolopyrimidine, method of their synthesis, pharmaceutical compositions based on thereof
HK1090354A1 (en) Novel dibenzo [b,f]oxepine-10-carboxamides and pharmaceutical uses thereof
CY1112057T1 (en) THERAPEUTIC PRODUCTS FOR AUTOMATIC ADMINISTRATION
EP1374868A4 (en) Remedies and/or preventives for diabetic ischemic heart diseases
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
CA2362833A1 (en) Phenylalaninol derivatives
MY122570A (en) Benzamide derivatives and drugs containing the same
TR199900584T2 (en) Azole fungicides containing amino acid esters.
AU8705198A (en) Remedies/preventives for respiratory diseases
PT966455E (en) OXYRANOCHARBOXYL ACIDS FOR THE TREATMENT OF DIABETES
WO2003045369A3 (en) Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses